Top View
- Press Release Nanobiotix Announces the Start of the Roadshow for Its Proposed Global Offering and Proposed Nasdaq Listing
- Nanobiotix Establishes Promising Preclinical Proof-Of-Concept in Immuno Oncology
- NBTX Starts Phase I-II Clinical Trial in Liver Cancers with Its Lead Product NBTXR3
- Nanobiotix Strengthens Its Nanoxray Pipeline with the Launch of NBTX-TOPO Development, the First Nanotherapeutic with Embedded Radar
- Nanobiotix Provides Second Quarter Operational and Financial Update
- PR-Greenshoe-Closing.Pdf
- Press Release Nanobiotix Receives Feedback from Us
- Press Release Nanobiotix Announces First Quarter
- Laurent Levy, Président Du Directoire, Se Renforce Au Capital De Nanobiotix
- Press Release Nanobiotix to Present Four Posters
- Corporate Presentation
- Press Release Nanobiotix Subsidiary Curadigm
- Chemical Mechanisms of Nanoparticle Radiosensitization and Radioprotection: a Review of Structure-Function Relationships Influencing Reactive Oxygen Species
- Press Release
- Nanobiotix to Present Preclinical Data on Nanoparticle Radioenhancer Nbtxr3 at the Aacr Annual Meeting 2017
- Press Release
- Press Release
- New Use of Metals As Nanosized Radioenhancers
- R E Se a Rc H a Rtic Le
- Laurent Levy, Pionnier En Nanomédecine, Est Élu
- Nanobiotix Presents Nbtxr3 Preclinical Data Demonstrating Its Potential Usage As in Situ Vaccine for Cancer at the Society for Immunotherapy of Cancer Annual Meeting
- Metals As Radio-Enhancers in Oncology: the Industry Perspective
- Press Release
- Nanobiotix Reports Successful Results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer
- GLOBAL DEVELOPMENT STRATEGY Nanobiotix Will Develop NBTXR3 Across Tumor Indications with Radiation Alone and in Combination with Other Therapies
- Correction to Release Dated May 19, 2021 PRESS RELEASE
- Nanobiotix Presented New Clinical and Pre-Clinical Data Confirming NBTXR3’S Significant Potential Role in Immuno-Oncology at SITC Annual Meeting
- The Future of Nanosized Radiation Enhancers
- Fda Approves Nanobiotix's First Immuno-Oncology Trial
- Press Release
- Global Development Strategy
- Laurent Levy, CEO of Nanobiotix, Receives the UB Entrepreneurship Award from the University at Buffalo, SUNY
- Press Release
- Global Development Strategy
- Press Release Nanobiotix Announces Key
- Nanobiotix Announces New Organizational Structure As the Company Enters Its Next Stage After First European Market Approval
- Nanobiotix and MD Anderson Cancer Center Announce a Large-Scale, Comprehensive Clinical Collaboration on NBTXR3
- First-In-Human Study Testing a New Radioenhancer Using
- Press Release Nanobiotix Announces Positive First Results for Novel Nbtxr3 in Rectal Cancer Study at Asco-Gi 2021
- Press Release Nanobiotix Announces Initiation of New Clinical Study Evaluating Nbtxr3 in Lung Cancer
- Global Development Strategy
- Press Release Nanobiotix Announces Positive First
- Press Release Nanobiotix 2020 Q4 and Annual Revenues
- Press Release